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 Our decision context and requirements 
 Choice of MCDA method 
 Pilot study with PROMETHEE II 
 Methods 
 Main results 
 Sensitivity analysis (esp. relevant!) 
 Discussion 
 Future work 
OVERVIEW 
 Decisions before drugs can be used: 
Market Access  Reimbursement  Prescribe 
 MCDA a structured and transparent method to guide process 
 Growing interest in health field (Diaby 2013, Marsh 2014, ISPOR 
taskforce) 
 Patient perspective important, can be measured with stated preference 
methods  This yields probabilistic preference data 
 
 How can we transparently integrate these (probabilistic) preferences 
in a structured MCDA process? 
OUR DECISION CONTEXT AND REQUIREMENTS 
PROBLEM DEFINITION 
 Broekhuizen 2015 review approaches to deal with uncertainty in MCDA 
(569 studies identified) 
OUR DECISION CONTEXT AND REQUIREMENTS 
WHAT MCDA METHOD TO USE IN CONJUNCTION WITH PROBABILISTIC DATA? 
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OUR DECISION CONTEXT AND REQUIREMENTS 
WHAT MCDA METHOD TO USE IN CONJUNCTION WITH PROBABILISTIC DATA? 
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Top 3 MCDA methods used with probabilistic approach 
 Goal: choose an antidepressant 
 Alternatives: Venlafaxine, Bupropion, Duloxetine 
 Criteria: 
1) Response to treatment 
2) Achieve remission 
3) Minor side effects 
4) Major side effects 
 Weights AHP panel session with 12 patients 
But method would readily extend to larger sample sizes 
 Performance scores derived from clinical trials that compared the drugs 
with placebo. 
 Modeled in Visual PROMETHEE (academic edition) and R 
THE PILOT STUDY 
DESCRIPTION 
THE PILOT STUDY 
SOURCE DATA 
  Benefits   Risks   
  Response Remission Adverse events Severe adverse 
events 
Median weight 
(range) 
0.62 (0.36 to 0.78) 0.16 (0.07 to 0.34) 0.04 (0.01 to 0.23) 0.19 (0.02 to 0.25) 
Odds ratio (95% CI)         
Dul vs Plc 1.95 (1.61 to 2.36) 1.91 (1.56 to 2.34) 1.91 (1.50 to 2.43) 0.96 (0.39 to 2.35) 
Ven vs Plc 2.04 (1.74 to 2.39) 1.97 (1.64 to 2.36) 1.80 (1.28 to 2.53) ‡‡ 1.27 (0.81 to 2.00) 
Bup vs Plc 1.48 (1.20 to 1.82) 1.46 (1.17 to 1.81) 1.55 (1.10 to 2.18) ‡‡ 0.39 (0.16 to 0.95) 
PREFERENCE FUNCTION USED 
MAIN RESULTS 
GLOBAL FLOWS AT AGGREGATE (GROUP) LEVEL AND FOR 9 PATIENTS 
 Response: [22%;100%],  
median = 62%, range 36% to 78% 
 Remission: [0%;100%],  
median = 16%, range 7% to 34% 
 Side effects: [0%;23%],  
median = 4%, range 1% to 23% 
 Severe side effects: [0%;46%],  
median = 19%, range 2% to 25% 
SENSITIVITY TO VARIATION IN WEIGHTS 
RANK STABILITY INTERVALS 
 Bootstrapping weights, repeat 1000 times 
SENSITIVITY TO VARIATION WEIGHTS 
PROBABILISTIC ANALYSIS 
V D 
B 
 Sample odds ratios from lognormal distribution 1000 times 
SENSITIVITY TO VARIATION WEIGHTS AND SCORES 
PROBABILISTIC ANALYSIS 
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COMPARISON WITH AHP RESULTS 
 It is possible to compare the preferences of a large group of patients with 
PROMETHEE 
 Group preferences and individual preferences can be contrasted 
 Results similar to AHP results 
 Problem: Visual PROMETHEE limited to 9 scenarios 
 The meaning of weights? 
 Can AHP weights really be used for PROMETHEE? 
 
 
DISCUSSION 
 Supporting decision in early stages of health technology 
 Case: novel imaging modalities for non-small cell lung cancer 
 Klaske Siegersma (MSc student) will elicit from group of clinical 
experts: 
 Relevant criteria 
 Criteria weights 
 Performance scores / preference functions 
 Piloting weights elicitation for PROMETHEE among patients 
 Problem: low numerical & health literacy 
 Incomparability? Veto? 
FUTURE WORK 
 More information: 
 H.broekhuizen@utwente.nl 
 http://www.utwente.nl/bms/htsr/Staff/broekhuizen/ 
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